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Introduction
The inheritance of e4 allele of apolipoprotein E (APOE) is the major genetic risk factor for late-onset Alzheimer's disease (Saunders et al., 1993) ; however the mechanisms underlying this association are elusive (Kim et al., 2009; Kanekiyo et al., 2014) . Compared to APOE3 and APOE2 carriers, patients with Alzheimer's disease with the APOE4 alelle are characterized by earlier onset of the disease and higher level of amyloid plaques (Huang and Mahley, 2014; Yu et al., 2014) .
ATP binding cassette transporter A1 (ABCA1) regulates cholesterol and phospholipids efflux from cells to lipid-poor apolipoprotein A-I (ApoA-I, encoded by APOA1), as well as other apolipoprotein acceptors such as apolipoprotein E (APOE), thus mediating the generation of high density lipoproteins (reviewed in Koldamova et al., 2014) . Prominent characteristics of patients with non-functional ABCA1 and Abca1 knockout mice (Abca1 ko ) is their virtual absence of circulating high density lipoproteins and ApoA-I in plasma and brain, and relatively low level of low density lipoproteins in the blood (Brooks-Wilson et al., 1999; Koldamova et al., 2014) . In addition, mice lacking ABCA1 exhibit a substantial reduction of APOE-containing lipoproteins accompanied by a significant decrease of total level of APOE protein in the brain (Wahrle et al., 2004) . Considering the prominent role that APOE plays in Alzheimer's disease risk, the fact that ABCA1 functionality can affect APOE lipidation or its total level might be of significance for the disease. In mouse models of Alzheimer's disease, Abca1 deficiency increased amyloid deposition in parallel with reduced APOE levels (HirschReinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al., 2005; Lefterov et al., 2009) . In contrast, Abca1 overexpression in PDAPP mice decreases amyloid burden (Wahrle et al., 2008) . Recently, we demonstrated that Abca1 haplodeficiency deferentially affects the phenotype of mice expressing human APOE3 or APOE4 isoforms suggesting that APOE4 isoform is more vulnerable to additional genetic effects (Fitz et al., 2012) .
The mechanism by which Abca1 deficiency affects amyloid deposition when APOE is significantly reduced and there is virtually no ApoA-I is not understood and difficult to reconcile with the data from single Apoe and Apoa1 knockout mice. So far all published studies demonstrated that the deletion of Apoe diminished amyloid pathology in different APP mouse models (Bales et al., 1997; Kim et al., 2011) . The expression of Apoa1 in APP transgenic mice reportedly affects cerebral amyloid angiopathy but has no effect on parenchymal amyloid plaques (Fagan et al., 2004; Lefterov et al., 2010; Lewis et al., 2010) . Interestingly, when the deletion of Apoe was accompanied by the absence of another brain apolipoprotein, apolipoprotein J (clusterin, encoded by Clu), the mice had earlier onset and increased amyloid deposition (DeMattos et al., 2004) .
In this study we used APP/PS1dE9 transgenic mice crossed to Apoe and Apoa1 knockout mice to generate Apoe/Apoa1 double-knockout mice (hereafter referred to as APP/DKO). We hypothesized that APP/DKO will replicate Alzheimer's disease-like phenotype of APP/Abca1 ko mice. We compared amyloid pathology, cognitive decline, and peripheral lipoprotein metabolism of APP/DKO to the phenotype of APP/ Abca1 ko mice and single knockout mice. Unexpectedly, and contrary to our prediction, the results demonstrated that the double deletion of Apoe and Apoa1 ameliorated the amyloid pathology and increased amyloid-b clearance. Furthermore, regardless of significantly decreased amyloid pathology, APP/DKO mice had substantial behaviour deficits and impaired dendrite morphology. Our data also suggest that the abnormal and very high level of plasma very-lowdensity lipoprotein/low-density lipoprotein (VLDL/LDL) in APP/DKO mice may affect amyloid-b clearance.
Materials and methods
Mice APP/PS1ÁE9 [B6.Cg-Tg(APPswe, PSEN1ÁE9)85Dbo/Mmjax] transgenic mice referred to as APP/WT and mice with targeted disruption of mouse Apoa1 (B6.129P2-Apoa-I tm1Unc /J, referred to as A ko ) or Apoe (B6.129P2-Apoe tm1Unc /J, referred to as E ko ), all strains on C57BL/6 J background, were purchased from Jackson Laboratory. Abca1 null mice on a C57BL/6 Â DBA/1 mixed background (DBA/1-Abca1 tm1Jdm /J, Abca1 ko ) were purchased from Jackson Laboratory and crossbred for 10 generations to pure C57BL/6 background in our laboratory. APP/WT mice were crossbred to either A ko , E ko , or Abca1 ko mice to generate APP/A ko , APP/E ko or APP/ Abca1 ko mice, respectively. Additionally, APP/WT, A ko , and E ko mice were crossed to generate APP mice deficient in Apoa1 and Apoe (referred to as APP/DKO) and non-APP expressing littermates (DKO). APP/WT mice with wild-type mouse Apoa1, Apoe, and Abca1 were used as controls. For the brain homogenate injection study we used the brains of APP23 transgenic (Koldamova et al., 2005) or wild-type mice. All mice for each line were littermates and housed on a 12-h light/dark cycle with ad libitum food and water. For all experiments, male and female mice were used. All animal procedures were performed in accordance with PHS policies and University of Pittsburgh's Institutional Animal Care and Use Committee. All reagents were purchased through Fisher Scientific unless noted.
Brain homogenate injections
Mice were anaesthetized with isoflurane, placed on a heating pad, surgical site shaven and disinfected. Bilateral stereotaxic injections of 2 ml of either APP23 or wild-type brain extract were infused into the hippocampus and overlying cortex (AP À2.5 mm, L AE2.0 mm, DV À1.0/À1.8 mm; 0.5 ml/min). Tris-buffered saline (TBS) brain extracts were obtained from a 23-month-old APP23 (Koldamova et al., 2005) and 24-month-old wild-type mouse. Following removal of the infusion needle the incision was sutured and mice monitored until fully recovered. Mice were infused at 3 months of age and amyloid pathology assessed 4 months later as described below.
Behavioural testing
Behavioural testing was performed during the light phase of the light/dark cycle. Contextual fear conditioning (Stoelting Co.) was performed as described previously . Briefly, mice were placed in a conditioning chamber for 2 min before the onset of a tone (conditioned stimulus, duration of 30 s, 85 dB sound at 2800 Hz). In the last 2 s of the conditioned stimulus, mice were given a 2 s, 0.7 mA footshock through the floor, and this cycle was repeated. Mice remained in the chamber for 30 s before being returned to their housing cages. Twenty-four hours later contextual fear conditioning was assessed by measuring freezing behaviour for 5 min in the original chamber. Cued fear learning was assessed 24 h after contextual testing by placing mice in a novel context for 2 min, after which they were exposed to the conditioned stimulus for 3 min, and freezing behaviour measured. Freezing behaviour, defined as the absence of movement except that needed for breathing, was recorded and scored using AnyMaze software (Stoelting Co.).
Multiple blood draws
Multiple blood draws were performed from the lateral saphenous vein as described elsewhere (Hem et al., 1998) . Mice were immobilized, hind leg held in the extended position, fur over the lateral saphenous vein shaved and the area cleaned with 70% alcohol wipes. A 25-gauge needle was used for saphenous venepuncture, gentle pressure was applied around the puncture sight and the equivalent of 0.5% of the animal's bodyweight collected and centrifuged for 5 min before plasma collection. Plasma amyloid-b levels were assessed by sandwich enzyme-linked immunosorbent assay (ELISA) as described below.
Tissue processing
Mice were anaesthetized with Avertin (250 mg/kg of body weight, intraperitoneally) and blood collected through cardiac puncture followed by transcardial perfusion with 25 ml of cold 0.1 M phosphate-buffered saline (PBS), pH 7.4 . Brains were rapidly removed and divided into hemispheres. The first hemisphere was quickly dissected into cortex, hippocampus, subcortical structures, and cerebellum and snap frozen on dry ice. The other hemisphere was drop fixed in 4% phosphate-buffered paraformaldehyde at 4 C for 48 h before storage in 30% sucrose. After minor arterial branching, adventitial and adipose tissues were removed, and the aorta was dissected from the heart to iliac arteries. The aortas were fixed in 10% neutral buffered formalin and stored at 4 C.
Histology and immunohistochemistry
All histological procedures for assessing amyloid pathology were as reported previously . HistoPrep TM -embedded hemibrains were cut in the coronal plane at 30 -mm sections and stored in a glycol-based cryoprotectant at À20 C until staining. Following staining all sections were cover slipped with gelvatol mounting media.
For X-34 staining, a series of five sections were selected 700 -mm apart, starting from a randomly chosen section $150 mm caudal to the first appearance of the CA3 and dentate gyrus. Mounted sections were washed in PBS for 10 min and stained with 1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-benzene (X-34) (100 mm) for 10 min. Following the staining, slides were rinsed with PBS and destained with 0.2% NaOH in 80% ethanol for 2 min. Finally, sections were washed with PBS.
For 6E10 staining, adjacent sections to X-34 stained sections were immunostained with 6E10 antibody (SIG-39340; Covance) . Briefly, free-floating sections were blocked for endogenous peroxidases, avidin-biotin quenched, and antigen retrieval was performed with 70% formic acid. Sections were then incubated in 6E10 biotinlabelled antibody (1:1000) at room temperature for 2 h before being developed with Vectastain ABC Elite kit and a DAB substrate (Vector Laboratories). Microscopic examination was performed using a Nikon Eclipse 80i microscope (Nikon Inc.; Â4 magnification). For quantitative analysis, staining in the cortex and hippocampus was defined as the percentage area covered by X-34 or 6E10 positivity using MetaMorph 7.0 software (Molecular Devices).
Neurite quantification
Neurite quantification was performed as previously described (Tapias et al., 2013; Tapias and Greenamyre, 2014) . For immunofluorescence labelling, five sections per animal starting at the beginning of the dentate gyrus and every 300 mm were rinsed three times in PBS for 10 min and permeabilized with 1% Triton TM X-100 in PBS for 5 h at 4 C. The tissue was washed in PBS and blocked with 10% serum and 0.3% Triton TM X-100 in PBS for 30 min at room temperature. The sections were incubated for 72 h at 4 C with MAP2 primary antibody (1:2000; #MAB378, Millipore) and washed with PBS. Sections were incubated with Cy3-conjugated secondary antibody (1:500; Jackson-ImmunoResearch) for 2 h at room temperature followed by a final PBS wash and counterstain with H33342 nuclear reagent (1:3000). The FilamentTracer module of Imaris (Bitplane) was used to determine hippocampal neuronal patterning. The MAP2 labelling was used to quantify total neurite length, the number of segments, and the number of branches in hippocampal CA1 and CA2 regions. For neurite analysis, four to five confocal images were acquired for the CA1 region whereas three to four were captured for the CA2 region. Confocal fluorescence micrographs were obtained using Â 60 magnification at very high resolution (100 ms). For unbiased examination, the size and the length of the neurites were the only parameters that required manual introduction. Neurite length was normalized to the number of H33342 stained nuclei.
Western blotting, ELISA and dot blotting
Frozen cortices and hippocampi were homogenized in TBS homogenization buffer (250 mM sucrose, 20 mM Tris base, 1 mM EDTA, and 1 mM EGTA, 1 ml per 100 mg of tissue) and protease inhibitors cocktail (Roche).
Amyloid-b ELISA was performed essentially as before (Fitz et al., 2012) . Briefly, for extraction of soluble amyloid-b, samples of the initial brain homogenate were centrifuged at 100 000g for 1 h, supernatant (TBS extract) was used to determine soluble amyloid-b, non-plaque-associated amyloid-b. Insoluble amyloid-b and plaque-associated amyloid-b was extracted from the remaining pellet by mixing with 70% formic acid. ELISA for amyloid-b was performed using 6E10 as the capture antibody and anti-Ab40 (G2-10 mAb) and antiAb42 (G2-13 mAb) monoclonal antibodies conjugated to horseradish peroxidase (The Genetics Company) as detection antibodies. The final values of amyloid-b were calculated based on amyloid-b 40 and amyloid-b 42 peptide standards (American Peptide) and normalized amounts of amyloid-b were expressed as pmol/mg of total protein.
For western blot, proteins extracted with TBS or radioimmunoprecipitation assay (RIPA) buffer were resolved on sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. For ABCA1 and APP detection, RIPA extracted proteins were resolved on 10% Tris-glycine gels and probed with anti-ABCA1 (Abcam) and 6E10 antibodies, respectively. For soluble amyloid-b and APP carboxy-terminal fragments, result of -secretase cleavage (CTF-), RIPA extracts were resolved on 4-12% BisTris gels probed with 6E10 antibody. b-Actin was used as a loading control for all western blots and detected by monoclonal antibody (Santa Cruz Biotechnology).
The level of soluble amyloid-b oligomers was measured by dot blot assay using TBS extract as before (Fitz et al., 2013) . One microgram of protein was spotted on nitrocellulose membrane and probed with A11 antibody (1:2000), specific for oligomeric forms of amyloid-b and generously provided by Dr Charles Glabe (University of California, Irvine). The immunoreactive signals were visualized using enhanced chemiluminescence detection kit (GE Healthcare) and quantified densitometrically. To normalize for total protein, the blots were stripped and stained with Coomassie blue reagent. We performed two dot blots with A11 antibody and used the mean value for quantification. As an additional control the exact same amounts of sample protein were spotted on separate dot blots and probed with 6E10 antibody followed by Coomassie blue staining to normalize for total protein. I (Perkin Elmer) using standard protocol provided with the Pierce Iodination Beads (ThermoFisher Scientific), which allows for maintaining biological activity of proteins. The resulting components underwent centrifuge filter purification and resolved by HPLC and purity analysed by mass spectrometry.
Amyloid
Surgery and radiotracer application was performed as described before with slight modifications (Cirrito et al., 2005; Deane et al., 2008) . Briefly, guide cannulas (22-gauge) with 5 mm projection from the pedestal (Plastics One) were stereotaxically implanted into the caudate-putamen of anaesthetized mice (AP + 0.9 mm, L À1.9 mm, DV À2.9 mm). Animals were allowed to recover 4-6 h after cannula implantation, to allow the blood-brain barrier to partially repair and exclude large molecules.
14 C-inulin and I-amyloid-b 42 were co-injected using a micropump, and animals sacrificed 30 min later and brains removed.
The percentage of radioactivity remaining in the brain after microinjection was determined as previously described (Deane et al., 2008) . Briefly, % recovery in brain = 100 Â (Nb/Ni), where Nb is the radioactivity remaining in the brain at the end of the experiment and Ni is the radioactivity microinjected into brain interstitial fluid, i.e. the disintegrations per minute for 
Fast protein liquid chromatography and cholesterol assay
Pooled serum samples (100 ml total) from five mice of each genotype were loaded on two Superose 6 columns (GE Healthcare) in an AKTA Explorer system (Amersham Pharmacia Biotech Inc.) and eluted with Dulbecco's phosphate-buffered saline (2.7 mM KCl, 1.5 mM KH 2 PO 4 , 140 mM NaCl, 6.5 mM Na 2 HPO 4 , 1 mM EDTA, pH 7.2) at 0.2 ml/min. Total cholesterol in each fraction (0.4 ml) was determined using Amplex Õ Red Cholesterol Assay Kit (Molecular Probes) in duplicate. Fluorescence was read on a Synergy 2 microplate reader (Biotek).
In addition VLDL/LDL were separated from high density lipoproteins in serum samples using the high density lipoproteins and LDL/VLDL Cholesterol assay kit (AB65390, Abcam).
Statistical analyses
All results are reported as means AE standard error of the mean (SEM). All statistical analyses were performed in GraphPad Prism, version 5.0 (La Jolla, CA) and differences considered significant where P 5 0.05.
Results
Effect of Apoe and Apoa1 double deficiency on amyloid-b level in APP/ DKO mice
Previously, we and others demonstrated that the deletion of Abca1 increased amyloid plaques in APP transgenic mice (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al., 2005) . The phenotype was accompanied by virtual absence of ApoA-I and a significant decrease of APOE protein in the brain. To examine how the deficiency of these two apolipoproteins affects amyloid deposition we generated Apoe/Apoa1 double-knockout mice and crossed them to APP/WT transgenic mice to obtain APP/DKO. The amyloid phenotype of APP/DKO was compared to APP mice lacking Abca1 (APP/Abca1 ko ) and to single Apoe (APP/E ko ) and Apoa1 (APP/A ko ) knockout mice. First, we evaluated the level of amyloid load using X-34 staining (Fig. 1A-C) . Surprisingly, the assessment of compact amyloid plaques visualized by X-34 in cortex (Fig. 1B) and hippocampus ( Fig. 1C) revealed that APP/DKO mice have significantly less amyloid load than APP/Abca1 ko mice. Compact amyloid load of APP/DKO did not differ significantly from single APP/E ko and was significantly lower than APP/A ko mice. The levels of diffuse amyloid plaques visualized by 6E10 antibody confirmed this result (Fig. 1D-F) . The effect of genotype on the level of X-34 and 6E10 plaques was not gender-dependent (data not shown). These experiments suggest that Apoe deficiency is the main factor that controls the effect of genotype on amyloid plaque load in APP/DKO mice and the deletion of Apoa1 does not contribute significantly.
Next we extracted soluble and insoluble amyloid-b from the brains of these mice and determined amyloid-b levels by ELISA. We found that the amount of soluble amyloid-b 40 and amyloid-b 42 were very low in APP/DKO and APP/E ko mice compared to the other three genotypes ( Fig. 2A and  B) . To confirm the result, we also performed western blot to measure soluble amyloid-b from APP/WT, APP/DKO and APP/Abca1 ko mice. As seen on the graph (Fig. 2C ) and the representative picture (Fig. 2D) , APP/DKO mice had significantly less amyloid-b compared to APP/Abca1 ko and APP/WT mice. Western blots did not show significant difference in the levels of ABCA1, full length APP, and -secretase cleavage (CTF-) between the different genotypes (Fig. 2D) . As expected, ApoA-I protein was missing in APP/DKO and APP/A ko mice. Similarly, APOE was not detected in APP/DKO and APP/E ko mice. As reported earlier, we detected a significant decrease of APOE protein in APP/Abca1 ko mice and virtual absence of ApoA-I (Koldamova et al., 2005) . To determine the level of APOE-containing high density lipoproteins particles in CSF we performed native gel electrophoresis. The results demonstrated substantial reduction of native APOE lipoproteins in the CSF of Abca1 ko mice and their absence in double knockout mice (Fig. 2E) . Finally, the results of insoluble amyloid-b 40 and amyloid-b 42 levels confirmed that double deletion of Apoe and Apoa1 reduced the level of deposited amyloid-b (Fig. 2F and G) . Similar to the effect on amyloid plaques, the amount of insoluble amyloid-b in APP/DKO mice was significantly lower than in APP/Abca1 ko and APP/A ko mice and indistinguishable from APP/E ko mice.
Soluble amyloid-b oligomers are increased in APP/Abca1 ko and unchanged in APP/DKO mice Previously we have shown that lack of one copy of Abca1 increases amyloid-b oligomers in APP23 mice (Lefterov et al., 2009) . To examine whether the double deficiency of Apoe and Apoa1 affects amyloid-b oligomers, we used A11 conformation-specific antibody (Fig. 3) which recognizes soluble amyloid-b oligomers (Kayed et al., 2003) . As shown in Fig. 3B , A11-positive oligomers detected in APP/ DKO did not differ significantly from those in APP/WT mice. In contrast, A11-positive oligomers were significantly increased in APP/Abca1 ko mice confirming our previous result (Lefterov et al., 2009) . Although there is a trend towards an increase in APP/Abca1 ko mice, no significant changes were detected in 6E10-positive aggregates.
In conclusion, the data presented on Figs 1-3 demonstrate that the effect on amyloid phenotype is mainly determined by the deletion of Apoe and that the lack of Apoa1 does not significantly contribute to amyloid deposition in APP/DKO mice.
Abca1 deficiency but not lack of Apoe and Apoa1 delays amyloid-b 40 and amyloid-b 42 clearance from the brain To examine how the lack of Apoe and Apoa1 affect amyloid-b efflux out of the brain we injected mice of all genotypes (not expressing human APP) with radioactivelylabelled amyloid-b using a modification of previously published method (Deane et al., 2004; Cirrito et al., 2005) . Mice that do not express human APP were used to avoid the interference of amyloid deposition on the clearance of exogenous amyloid-b. The results (Fig. 4A and B) demonstrate that Abca1 deficiency significantly decreased amyloid-b clearance through the blood-brain barrier and the effect is more pronounced on 125 I-amyloidb 42 efflux. In contrast, the deficiency of Apoe in double knockout and E ko mice significantly increased amyloid-b efflux from CNS compared to APP/WT and APP/Abca1 ko . The effect was not related to the disruption of blood-brain barrier as demonstrated by Evan's blue experiments ( Supplementary Fig. 1 ). Our conclusion is that the deficiency of Abca1 delays the export of amyloid-b from the brain and deficiency of Apoe increases amyloid-b clearance.
Effects of Abca1, Apoa1 and Apoe genotypes on the dissemination of exogenous amyloid-b seeds Previous studies demonstrated that brain extract from old APP expressing mice injected into the brain of young mice effectively disseminates thus forming amyloid-b plaques in areas far from the injected side (Meyer-Luehmann et al., 2006) . To test how the deficiency of Abca1 or Apoe affects the spreading of exogenous amyloid-b seeds, young predepositing APP mice of various genotypes were injected with amyloid-b seeds from 24-month-old APP23 mouse (labelled as ' + '). The injected material was a soluble TBS extract from brain that usually contains amyloid-b monomers or oligomers, but not fibrils (Lefterov et al., 2009) . The control mice of the same genotypes were injected with TBS extract from 24-month-old wild-type littermates (labelled as 'À'). Three months later, amyloid deposition in these mice was examined using X-34 staining for compact amyloid. As seen in Fig. 5 , all genotypes had significantly more amyloid when inoculated with APP23 extract than their counterparts injected with wild-type Compact amyloid was visualized using X-34 (A-C) and diffuse amyloid plaques were stained with 6E10 anti-amyloid-b antibody (D-F). Analysis is by one-way ANOVA with Tukey's post-test for multiple comparisons (shown on each graph). For both staining we used 6-7-month-old male and female mice: APP/WT (n = 10), APP/Abca1 ko (n = 10), APP/DKO (n = 9), APP/E ko (n = 10), APP/A ko (n = 9). (A) Representative X-34 pictures for all genotypes. Quantification of X-34 staining in cortex (B) and in hippocampus (C). ANOVA for cortex and hippocampus is P 5 0.0001. Post-test for hippocampus, APP/DKO versus APP/WT P 5 0.05; APP/E ko versus APP/WT, P 5 0.05. (D) Representative 6E10 staining for all genotypes.
Quantification of 6E10 staining in cortex (E) and in hippocampus (F). ANOVA for cortex and hippocampus is P 5 0.01. homogenate. However the different genotypes varied in the magnitude of their response to injected exogenous amyloid: whereas APP/Abca1 ko augmented amyloid plaque level by 410-fold, the increase seen in APP/DKO mice was $2-fold. Similarly, APP/E ko mice displayed a similar response in spreading of exogenous amyloid-b seeds. The response of APP/WT and APP/A ko was intermediate. The appearance of amyloid plaques was consistent with the pattern of the amyloid deposits in APP/WT mouse model and differed significantly from that in APP23 mice. This suggests that injected amyloid-b served as a seed to increase the amyloid deposition typical of the host model and did not transmit the amyloid phenotype of the donor APP23.
Effects of Abca1, Apoa1 and Apoe deletion on atherosclerosis, peripheral lipoproteins and amyloid-b level in plasma
The Apoe-knockout mouse is a well-described model for atherosclerosis (Plump et al., 1992) . To determine how the deletion of both Apoe and Apoa1 affect atherosclerosis in APP transgenic mice, we examined the level of atherosclerotic plaques in the aorta and compared to single knockout mice. As expected, the level of atherosclerosis in APP/WT was negligible (0.34%) and significantly increased in APP/E ko mice (16.5%) (Supplementary Fig.  2A and B). Consistent with previous data for Abca1 ko (Zhao et al., 2011) and Apoa1-knockout mice (Parolini et al., 2005) , APP/Abca1 ko and APP/A ko mice had very low levels of atherosclerotic plaques (0.28 and 0.23%, respectively). Surprisingly, the atherosclerosis in APP/DKO mice (12.4%) was statistically undistinguishable from the observed level in APP/E ko mice. We also noticed that wildtype littermates (E ko versus APP/E ko , P 5 0.05 and DKO versus APP/DKO, P 5 0.01) had less atherosclerotic plaques compared to their APP counterparts ( Supplementary  Fig. 2B ). This suggests that amyloid-b deposition can contribute to atherosclerosis, however, only in genetically predisposed mice as the difference between APP/WT and wild-type mice was not apparent.
We next examined the plasma lipid profiles of APP/WT, APP/Abca1 ko , APP/DKO, APP/E ko and APP/A ko mice at 12 months of age. As shown on Fig. 6A , the lipid profiles of APP/E ko and APP/DKO were consistent with their were measured in the soluble fraction (cortex and hippocampus) by dot blot using conformation specific A-11 antibody. The intensity was normalized on total protein (TP) as measured by Coomassie blue staining. For comparison, dot blotting of the same samples probed with 6E10 antibody is shown. Analysis is by one-way ANOVA, P 5 0.05, followed by Tukey's post-test. n = 10 male and female mice per group. N.S. = not significant. atherosclerotic phenotype and their VLDL/LDL levels were very high as shown previously for double knockout and ApoE ko mice without APP transgene (Thorngate et al., 2003) . In contrast, APP/Abca1 ko lacked detectable high density lipoproteins. The high density lipoprotein fraction of APP/A ko mice was shifted to the left, towards lower density, consistent with high density lipoproteins containing mainly APOE. An alternative method to measure the level of LDL cholesterol was carried out and confirmed that VLDL/LDL levels in APP/E ko mice were 20 times higher and in APP/DKO mice 14 times higher than in APP/WT mice (Fig. 6B) . Using the same method, VLDL/LDL fraction in in APP/Abca1 ko mice were almost undetectable. Amyloid-b was reported to bind plasma lipoproteins (LaDu et al., 2012) . We reasoned that the very high level of VLDL/LDL in APP/E ko and APP/DKO mice can change the balance of amyloid-b on the two sides of the bloodbrain barrier and increase its clearance from the brain. To examine how plasma amyloid-b level was affected by the genotype, blood was withdrawn from the lateral saphenous vein of APP/WT, APP/Abca1 ko and APP/DKO mice at several time points for each mouse from 4 to 7 months of age and amyloid-b 42 level determined. As seen in Fig. 6C , APP/ DKO mice had the highest level of amyloid-b 42 in plasma and APP/Abca1 ko the lowest. Figure 6D shows Lack of Abca1 and double deficiency of Apoa1 and Apoe equally increases behaviour deficits in APP mice and non-transgenic littermates
To examine the effects of Abca1 deletion and double deficiency of Apoa1/Apoe on memory, 7-month-old mice were tested in a contextual cued fear conditioning paradigm. Non-transgenic Abca1 ko or double knockout mice were used as controls. As shown on Fig. 7A , during the contextual fear conditioning phase of testing, APP/Abca1 ko mice demonstrated a significant reduction in freezing time when compared to APP/WT mice (one-way ANOVA, P 5 0.01, post-test P 5 0.05). Similarly, APP/DKO mice showed a significant reduction in freezing time when compared to APP/WT mice (post-test, P 5 0.01). This demonstrates impaired fear memory in both APP/Abca1 ko and APP/ DKO mice compared to APP/WT mice. Cued phase of test, 48 h following the initial paradigm acquisition, showed no statistical difference in the performance of the mice (Fig. 7B) . Importantly we observed exactly the same significant difference between non-transgenic control genotypes during the cued phase of the fear conditioning paradigm ( Fig. 7C and D, respectively) . This experiment suggests that double deficiency of Apoa1 and Apoe affects behaviour performance regardless of amyloid plaques or soluble amyloid-b level.
Deletion of Apoe and Apoa1 impacts dendrite architecture
To determine how the deletion of both Apoe and Apoa1 impacts dendrite morphology in APP transgenic mice, two different regions (CA1 and CA2) of the medial hippocampus were examined. Quantitative analysis revealed that CA1 region of hippocampus showed a significant decrease in dendrite length (P 5 0.05), number of branch points (P 5 0.05) and number of neurite segments (P 5 0.05) in APP/Abca1 ko mice when compared to APP/WT mice ( Fig.  8A and B) . Interestingly, deletion of both Apoe and Apoa1 (Ab42, B) into the caudate-putamen. Clearance was assessed 30 min following this injection. 14 C-inulin was co-injected in each experiment to assess bulk flow elimination from the interstitial fluid. n = 3-5 mice per group. One-way ANOVA followed by Tukey's post-test was used to analyse the difference. N.S. = not significant; BBB = blood-brain barrier.
resulted in a substantial negative impact on neurite morphometry. APP/DKO displayed a significant decrease in total neurite length (P 5 0.01) and both number of branch points (P 5 0.001) and segments (P 5 0.001) relative to APP/WT mice. The data were normalized to the number of neurons and there was no significant change in the number of H3342-positive nuclei between all genotypes. Neurite architectural changes were restricted to the CA1 region of the hippocampus as we did not observe any gene effect in the CA2 region when comparing genotypes ( Fig. 8C and D ). Our data demonstrate that the deficiency of APOE and ApoA-I proteins potentiates neurite Figure 5 Effects of Abca1, Apoa1 and Apoe genotypes on the dissemination of exogenous amyloid-b seeds: Three-month-old predepositing APP mice of different genotypes were injected with amyloid-b seeds from 23-month-old APP23 mouse (labelled as ' + ') and amyloid-b plaques evaluated 3 months later using X-34 staining. Control mice were injected with brain homogenate from 24-month-old wild-type mouse (labelled as 'À'). Analysis is by one-way ANOVA (P 5 0.001) with Tukey's post-test (shown on the graph). n per group: APP/WT ( + ) = 8; APP/WT (À) = 6; APP/Abca1 ko = 6 per each group; APP/DKO and APP/E ko = 4 mice/group and APP/A ko = 3 mice/group. degeneration in the hippocampus, and this effect was CA1 region-specific.
Discussion
In this study we examined the effect of Apoe and Apoa1 double deletion on amyloid pathology, behaviour and neurite morphology in APP transgenic mice. The results were compared to the effect of Abca1, Apoe or Apoa1 single deletions in the same Alzheimer's disease model. The conclusion is that in APP/DKO mice, the effect of Apoe deletion on amyloid-b deposition and clearance is dominant whereas the deficiency of Apoa1 does not induce changes of those parameters. In contrast, simultaneous deletion of Apoe and Apoa1 significantly aggravates memory impairment, has a negative impact on dendrite architecture, and increases aortic atherosclerosis.
As mentioned in the 'Introduction' section, APP mice lacking Abca1 display increased amyloid deposition accompanied by virtual absence of ApoA-I protein and significantly decreased level of APOE. This study was rationalized on the assumption that the deletion of both Apoe and Apoa1 in APP mice would affect amyloid phenotype in a similar manner as the lack of Abca1. Surprisingly, we discovered that APP/DKO mice differed significantly from APP/Abca1 ko and in fact recapitulated the effect of Apoe deletion on amyloid deposition and clearance. Our data demonstrate that APP/DKO mice have significantly less X-34 (Fig. 1A-C ) and 6E10-positive amyloid plaques ( Fig. 1D-F) and insoluble amyloid-b ( Fig. 2F and G) compared to APP/Abca1 ko . Furthermore, APP/DKO similarly to APP/E ko mice, have very little soluble amyloid without any effect on APP processing (Fig. 2D) suggesting that amyloidb clearance is accelerated by the lack of APOE. This conclusion is supported by experiments that measure clearance showed worse amyloid phenotype and strongest reaction to exogenous amyloid: (i) lack of ABCA1 is accompanied by absence of APOE-containing high density lipoproteins in CNS (Wahrle et al., 2004) and this increases aggregation of the endogenous amyloid-b or exogenously injected amyloid-b seeds. Previously we have shown that high density lipoproteins particles decrease amyloid-b aggregation in vitro (Lefterov et al., 2010) therefore this can be a plausible explanation; (ii) clearance of amyloid by microglia, both endogenous and exogenous, is impaired in Abca1 ko mice because of the lack of brain high density lipoproteins. Prior studies demonstrated the significance of APOEcontaining lipoproteins for microglia-mediated amyloid-b clearance Terwel et al., 2011); and (iii) as the efflux of amyloid-b out of the brain in Abca1 ko mice is significantly diminished it allows amyloid-b concentration in the brain to reach the critical level needed to form amyloid-b seeds and to accelerate aggregation. These scenarios, however, still do not clarify why the complete absence of APOE and ApoA-I proteins ameliorates the amyloid pathology in APP/DKO mice.
So far, in vivo data have consistently demonstrated that the absence of Apoe decreases compact amyloid plaques in the brain (Bales et al., 1997; Holtzman et al., 2000a, b; Fryer et al., 2003) . In support of this, amyloid-b clearance experiments demonstrate that APOE delays amyloid-b efflux from the brain Deane et al., 2008) . More recent reports established that amyloid pathology is significantly decreased by eliminating only one Apoe allele in mice expressing human APOE4 or APOE3 isoforms (Kim et al., 2011; Bien-Ly et al., 2012) . Therefore, Figure 7 Effects of Abca1, Apoa1 and Apoe deletion on contextual and cued fear conditioning memory. Seven-month-old mice of various genotypes were examined for changes in memory performance using a contextual cued fear conditioning paradigm. Twenty-four hours after the initial acquisition of the contextual fear conditioning (A) the contextual test demonstrates that deletion of Abca1 or ApoA1 and Apoe in APP expressing mice significantly worsens memory performance. Forty-eight hours after the initial acquisition the cued phase of test showed no statistical differences between genotype (B). Similar change in memory performance of non-APP expressing mice that had an Abca1 or ApoA1 and Apoe deletion was observed in the contextual (C) but not in cued (D) phase of training. Analysis by one-way ANOVA with Tukey's post-test. n = 13-25 male and female mice per genotype. N.S. = not significant.
the conclusion from studies with Apoe knockout and hemizygous mice is that the presence of APOE in the brain retains amyloid-b in CNS and delays its clearance. In regard to Apoa1, there are two studies demonstrating that Apoa1 deletion does not affect parenchymal amyloid plaques (Fagan et al., 2004; Lefterov et al., 2010) . In addition, Apoa1 transgenic overexpression is not sufficient to affect the process of b-amyloidosis (Lewis et al., 2010) . Interestingly, both Lefterov et al. (2010) and Lewis et al. (2010) demonstrated that ApoA-1 affects the level of vascular amyloid and cerebral amyloid angiopathy. In our present work, the APP/A ko mice did not show any significant difference in parenchymal load compared to APP/WT controls, and we did not examine cerebral amyloid angiopathy.
At the same time, it seems difficult to reconcile the phenotype of APP/Abca1 ko mice that have less APOE protein but significantly higher levels of amyloid when compared to APP/DKO and APP/E ko mice. Therefore in a search for an explanation for these seemingly unreconciled facts, we turned the attention to other phenotypic characteristics of Abca1 ko and ApoE ko mice. A search of the literature and our data shown on Fig. 6 lead to the conclusion that a major difference between APP/ Abca1 ko and APP/E ko mice is their very distinct lipoprotein metabolism. ABCA1 regulates cholesterol efflux and high density lipoproteins metabolism, therefore the major consequence of its deletion is the near absence of high density lipoproteins and relatively low LDL (Fitz et al., 2012; MAP2 and H3342 staining were used for dendritic tree reconstruction in the hippocampal CA, and CA2 regions of APP/WT, APP/Abca1 ko and APP/DKO mice. Data were analysed from a total of four images ( Â60 confocal imaging) from each of the three sections for each mouse (n = 5 per group). The total dendritic length, branch points and segments were quantified using Imaris filament tracing macros and were normalized to the total H3342 positive nuclei of the CA1 (A and B) and CA2 (C and D) regions. Analysis by one-way ANOVA with Tukey's post-test. Panel A shows representative images for CA1 region and B shows the quantification of neurites length, branches and segments. In C, representative images for CA2 region and D the quantification of neurites length, branches and segments in this region. Note that deletion of Abca1 as well as the deletion of Apoa1 and Apoe significantly impacts neurite length, segments and branch points only in the CA1 region of the hippocampus. N.S. = not significant. Koldamova et al., 2014; Westerterp et al., 2014) . In contrast, lack of APOE, a ligand essential for lipoprotein clearance, leads to severe hypercholesterolaemia and spontaneous atherosclerosis (Plump et al., 1992; Breslow, 1996) . We have shown here that APP/DKO and APP/E ko mice have significantly more plasma cholesterol, mainly in the form of VLDL/LDL, compared to APP/WT mice. In contrast, APP/Abca1 ko mice had the lowest level of plasma lipoproteins (high density lipoproteins and VLDL/ LDL). One possibility which we have explored, was to measure how the level of plasma lipoproteins affects peripheral amyloid-b concentrations. As shown on Fig. 6C , the level of plasma amyloid-b 42 in APP/DKO mice was significantly higher compared to APP/Abca1 ko at all of the examined time points. This result suggests the probability that significantly higher plasma levels of VLDL/LDL in APP/ DKO mice could stimulate amyloid-b efflux out of the brain by the 'peripheral sink' mechanism. Initially, the peripheral sink hypothesis for amyloid-b clearance was proposed by DeMattos et al. (2001) to explain the decreased amyloid load in the brain after peripheral administration of anti-amyloid-b antibody. Data from patients and experimental animals support this hypothesis. A cross-sectional study showed that an increased brain amyloid-b is accompanied by lower peripheral levels of amyloid-b in patients with mild cognitive impairment (Devanand et al., 2011) and another more recent report demonstrated that lower plasma amyloid-b levels are associated with an increased risk of Alzheimer's disease (Chouraki et al., 2015) . Studies in mice also support the peripheral sink hypothesis: for example increased levels of amyloid-b binding molecules in plasma such as gelsolin (Gregory et al., 2012) or circulating lipoprotein receptors can affect amyloid-b level in the brain. Further support are data from our group demonstrating that plasma high density lipoprotein levels in APOE3 and APOE4 mice with one copy of Abca1 is significantly decreased and negatively correlated to amyloid-b plaque load (Fitz et al., 2012) . In the same study we showed that APOE3 and APOE4 mice with higher amyloid-b 42 levels in plasma have fewer X-34-positive plaques, suggesting an increased efflux out of the brain (Fitz et al., 2012) . In regard to cognitive performance, we have previously shown that APP mice with one copy of Abca1 perform significantly worse in a Morris water maze paradigm than mice with intact Abca1 in correlation to the level of soluble amyloid-b oligomers (Lefterov et al., 2009) . Herein, we confirmed the behaviour deficits caused by Abca1 deletion using another behaviour test-contextual fear conditioning. Surprisingly, APP/DKO mice displayed significant memory deficits in this test that are indistinguishable from APP/ Abca1 ko mice (Fig. 7) . The effect was unrelated to amyloid deposition, as non-transgenic controls showed similar performance in this paradigm. The effect was also unrelated to the soluble amyloid-b oligomers as APP/DKO mice had a similar level of oligomers compared to APP/WT mice ( Fig.  3A and B ). Our conclusion is that lack of brain APOEcontaining lipoproteins in the case of double knockout mice and their significant decrease in Abca1 ko mice affects memory regardless of amyloid-b oligomers and amyloid-b plaques.
Consistent with the behaviour data, are the results obtained for dendritic architecture (Fig. 8) . Both APP/ DKO and APP/Abca1 ko mice demonstrated significant impairment in neurite length and the number of branches and segments, compared to APP/WT mice. Previous studies demonstrated that APOE has an isoform-specific effect on dendrite morphology in mice and in patients (Schonheit et al., 2007; Dumanis et al., 2009; Nwabuisi-Heath et al., 2014) . Deficiency of Apoe reduces the number of synapses (Diaz-Cintra et al., 2004) , affects hippocampal reactive sprouting response following lesions in entorhinal cortex (Champagne et al., 2005) , and decreases MAP2-positive staining of neurons in amygdala (Robertson et al., 2005) . Apoe knockout mice challenged with kainic acid have a significant loss of synaptophysin-positive presynaptic terminals and MAP2-positive dendrites in the neocortex and hippocampus (Buttini et al., 1999) . However, it remains elusive how APOE can cause these effects on neurons. One plausible explanation is that APOE (as the main carrier of cholesterol and phospholipids in the brain) delivers these lipids to neurons. APOE is secreted by glial cells and serves as an acceptor for cholesterol and phospholipids during the process of cholesterol efflux mediated by ABCA1 (Abad-Rodriguez et al., 2004) . Regardless of evidence that adult neurons can synthesize cholesterol (Dietschy, 2009) , they rely on exogenously supplied lipids especially during periods of increased demands such as repair and increased synaptic activity (Pfrieger and Barres, 1997) . Therefore, the similarities in the dendritic morphology of APP/Abca1 ko and APP/DKO mice could be explained by the fact that they both lack APOE-containing high density lipoproteins in CNS.
In conclusion, our study demonstrates that the absence of both APOE and ApoA-I proteins has a favourable effect on amyloid pathology probably as a result of the increased amyloid-b clearance. In contrast the double deletion of these apolipoproteins causes deficits in cognitive performance and dendritic morphology. Thus, these findings emphasize the importance of APOE and ApoA-I for cognition and presents novel opportunities for therapeutic intervention.
